FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group

Ralf‐Dieter Hofheinz, Salah‐Eddin Al‐Batran, Georg Martin Haag et al.|Journal of Clinical Oncology|2022

Cited by 97